Vision Testing Systems in Massachusetts

Optos PLC manufactures ultra-widefield retinal imaging systems for ophthalmology and optometry practices. The company specializes in optomap technology, which captures single-shot 200-degree ultra-widefield retinal images in a non-mydriatic format, enabling clinicians to visualize the peripheral retina without pupil dilation. Products include the optomap platform with multiple generations and the recently announced Silverstone RGB system, representing advances in retinal imaging technology. Optos provides comprehensive clinical decision support through optomap Recognizing Pathology, a searchable reference resource with case libraries organized by pathology type and imaging modality to assist healthcare professionals in identifying retinal pathology. The company operates a support portal offering self-help solutions and product guidance. Optos devices are widely deployed in eye care settings globally, serving ophthalmologists, optometrists, and eye care centers. The ultra-widefield imaging capability addresses a clinical need for comprehensive retinal assessment, particularly for detecting peripheral retinal disease, diabetic retinopathy, age-related macular degeneration, and other posterior segment pathologies. Products integrate with OCT (optical coherence tomography) scanning capabilities, providing multi-modal diagnostic imaging.

Zoomax Technology manufactures electronic vision aids and digital magnification devices designed for low vision and age-related macular degeneration. The company produces portable digital magnifiers, handheld magnifiers, electronic glasses, and desktop magnification systems. Primary products include the Snow Pad (portable digital magnifier with iPad integration), Snow 12 (12-inch screen portable magnifier), Luna 6 (handheld magnifier), and Acesight VR (wearable electronic glasses for television viewing). These devices are marketed toward individuals with vision loss, ophthalmology practices, educators, and institutions serving visually impaired populations. Zoomax devices enable reading, writing, educational engagement, and television viewing by providing magnified digital displays. The company offers a 30-day free trial and 2-year warranty on products. Distribution appears to be direct-to-consumer and through healthcare providers and educational institutions. No specific FDA, ISO, or CE certifications are mentioned on the fetched homepage.

Cassini Technologies B.V. is an ophthalmic diagnostic and surgical planning solutions company headquartered in The Netherlands with US operations in Massachusetts and Florida. The company specializes in corneal diagnostics and intraoperative guidance systems for cataract and refractive surgery. Their core product line includes the Cassini Ambient, a corneal topography and biometry device that captures anterior and posterior corneal data using multicolor visible LEDs combined with infrared illumination, enabling highly repeatable measurements for toric intraocular lens (IOL) planning and astigmatism management. The Cassini Connect OR platform integrates preoperative diagnostics with intraoperative guidance, presenting surgical reference information in the operating room and supporting workflow continuity. The system features iris registration technology for automated cyclotorsion compensation and direct integration with femtosecond laser-assisted cataract surgery (FLACS) platforms including CATALYS and LENSAR, streamlining data transfer and reducing transcription errors. Cassini's solutions are designed to improve surgical accuracy and predictability, particularly for toric IOL placement and astigmatism correction. The company works with cataract surgeons, refractive specialists, and surgical centers across the US and internationally, emphasizing user-friendly operation, fast image acquisition, and open platform architecture enabling partnerships with major ophthalmic equipment manufacturers including Leica Microsystems. Clinical evidence demonstrates improved outcomes in toric lens volume, reduced prediction error in IOL power calculations, and enhanced astigmatic outcomes comparable to prevalent biometry combined with intraoperative aberrometry.

Rebion, Inc. commercializes Neural Performance Scanning (NPS), a proprietary technology platform that measures neurophysiologic mechanisms of the optic nerve/brain continuum through retinal scanning. The company's primary product, Blinq®, is an FDA-cleared portable point-of-care neural performance scanner designed for pediatric vision screening. Blinq directly detects micro-strabismus and amblyopia (lazy eye) by quantifying bilateral fixation and saccadic eye movements, achieving up to 100% sensitivity and over 90% specificity in clinical evaluations. The device performs a 3-second neural performance scan capable of detecting binocularity impairments associated with as little as 1-degree misalignment. Rebion's technology is supported by peer-reviewed clinical studies and research conducted at major medical institutions. The company also develops Traq™, an investigational device leveraging NPS to measure visual tracking impairments for clinical research purposes (currently not available for sale in the United States). Rebion serves diverse markets including community screeners, schools and administrators, clinical staff, parents, and caregivers. The platform enables early disease detection, intervention, and customized treatment across clinics, schools, and public health initiatives, reducing unnecessary referrals while improving diagnostic accuracy and patient outcomes.

Diagnosys LLC is a specialized manufacturer of visual electrophysiology test systems for both preclinical research and clinical ophthalmology practice. With over 40 years of market presence, the company designs and manufactures hardware and software for measuring visual function through electroretinography (ERG), pattern electroretinography (PERG), visually evoked potentials (VEP), and related electrophysiological testing modalities. The company's product portfolio spans three major categories: (1) Preclinical systems, including the proprietary Celeris® platform for rodent testing with dual-function stimulator-electrodes and ERG solutions for small to large animals; (2) Clinical visual function test systems encompassing visual electrophysiology, visual psychophysical testing, objective acuity measurement, and pupillometry; and (3) Trial services including study setup assistance, operator training, and quality assurance data review for multi-site clinical research. Diagnosys serves a global customer base that includes leading academic medical centers, eye institutes, and specialty ophthalmology practices such as Mayo Clinic, Bascom Palmer Eye Institute, Cleveland Clinic, Moorfields Eye Hospital, and Wilmer Eye Institute. The systems are used across multiple ophthalmology subspecialties: retina (inherited retinal diseases), glaucoma, pediatric ophthalmology, and neuro-ophthalmology. The company also actively supports clinical trial infrastructure with 35+ years of trial services experience. Key capabilities include in-house hardware and software design, patented and trademarked platforms, and extensive clinical validation across academic and research institutions worldwide. The company participates in major scientific conferences (ARVO, Society for Neuroscience) and provides continuing education webinars on visual electrophysiology methodology.

machineMD AG is a medical device company founded at the University Hospital of Bern, Switzerland, specializing in non-invasive neuroophthalmological diagnostic equipment. The company develops neos®, a proprietary neurophthalmoscope platform designed for automated, quantitative assessment of eye movements, pupils, and visual fields. neos® enables standardized, objective measurement of neuroophthalmological function across primary, secondary, and tertiary care settings, reducing operator variability and extending specialist-level diagnostic capability to underserved clinical environments. The platform incorporates quantitative pupillometry and oculometric analysis with demonstrated clinical applications across neurological and ophthalmological indications including multiple sclerosis, myasthenia gravis, Parkinson's disease, Alzheimer's disease, Huntington's disease, stroke, traumatic brain injury, age-related macular degeneration, and other neurodegenerative and neuro-ophthalmological conditions. machineMD operates facilities in Bern, Switzerland (headquarters at Weyermannsstrasse 36, 3008 Bern) and Cambridge, Massachusetts (1 Broadway, Cambridge, MA 02142). The company maintains active clinical partnerships with major Swiss academic hospitals including University Hospital Lucerne (LUKS), Inselspital Bern, and Universitätsspital Zürich, and international collaborations. Regulatory pathway and specific FDA/CE certification status not detailed on accessible site content.

PlenOptika is a medical technology company specializing in portable vision care diagnostics. The company manufactures handheld autorefractors and keratometers based on wavefront aberrometry technology, with a primary focus on expanding access to refractive error measurement in clinical, retail, and mobile care settings. The flagship product line consists of QuickSee Free (handheld autorefractor) and QuickSee Free Pro (autorefractor with keratometry capability), both designed for optometrists, ophthalmologists, optical retailers, and mobile health programs. These devices employ a proprietary Wavefront Refraction Engine to deliver clinical-grade autorefraction measurements from a lightweight, handheld platform. The QuickSee Free Companion App provides advanced clinical analytics including wavefront aberrometry data, visual acuity simulations, Zernike coefficients, and generates printable patient reports with clinical recommendations. PlenOptika targets vision professionals in developed markets and global health organizations serving underserved populations in developing regions. The company has been recognized with multiple clinical and innovation awards, including the Silmo d'Or 2023, Prism Awards, and recognition from the American Academy of Ophthalmology. QuickSee Free has been selected for space flight research applications, including deployment on the Polaris Dawn mission, demonstrating the device's clinical reliability. The company emphasizes addressing the global burden of refractive error and myopia epidemic through innovative, portable diagnostic tools that overcome limitations of traditional fixed-location eye care delivery models.

Heidelberg Engineering GmbH is a global leader in ophthalmic imaging and data solutions, founded in 1990 and trusted by eye care professionals in over 120 countries. The company specializes in high-precision diagnostic imaging systems for anterior and posterior segment ophthalmology, coupled with integrated healthcare IT solutions optimized for eye care workflows. Core product portfolio includes SPECTRALIS (multimodal retinal imaging platform), ANTERION (anterior segment imaging platform), Heidelberg Eye Explorer (ophthalmology-specific healthcare IT), and a fully digital surgical visualization platform. These solutions enable early disease detection, visualization of subtle retinal and anterior segment changes, treatment guidance, and reproducible high-definition imaging with seamless clinical infrastructure integration. The company operates a robust global support infrastructure with multilingual service capabilities and distributes products across diverse markets including academic medical centers, private practices, and research institutions. Heidelberg Engineering operates the Heidelberg Engineering Academy, providing over 20 years of continuous clinical education, hands-on training, and on-demand learning resources for eye care professionals worldwide. The company demonstrates strong commitment to scientific innovation through collaboration with leading research institutions and participation in major ophthalmic symposia (ISS, ARVO). Manufacturing and regulatory certifications align with medical device standards for ophthalmology markets.

Luminopia Inc. is an FDA-cleared digital therapeutics company specializing in VR-based treatment for pediatric amblyopia (lazy eye) in children aged 4–12. The company delivers its prescription-only Luminopia software through commercially available VR headsets, enabling patients to receive binocular vision therapy while watching curated TV content instead of traditional patching. The treatment regimen requires one hour daily, six days weekly, with clinical trials demonstrating significant vision improvement within 4–12 weeks. Luminopia is prescribed by ophthalmologists, optometrists, and orthoptists; the company handles fulfillment, patient support, and compliance monitoring. Designed for at-home use alongside corrective lenses, Luminopia achieved 94% parental preference over conventional patching and demonstrated 85% median treatment completion rates, addressing the long-standing compliance challenges in amblyopia management.

Phelcom Technologies is a medical device manufacturer specializing in portable ophthalmic imaging solutions. The company designs and produces the Eyer and Eyer2 portable fundus cameras—high-quality, portable retinal imaging devices capable of capturing fundus images with 55 degrees of visual field and anterior segment photography. Eyer2 represents their latest iteration, marketed as the world's first high-quality portable fundus camera. The company operates a cloud-based image management platform, EyerCloud, enabling automatic and secure exam storage and accessibility. Phelcom's devices are positioned for use in diverse clinical settings including private optometry practices, ophthalmology clinics, pediatric care, and remote/resource-limited environments. The Eyer devices have been featured in peer-reviewed research and are approved by regulatory bodies including ANVISA (Brazilian health authority, Class II medical device) and cleared for use in multiple countries. The company provides training and support services for end users and maintains a US headquarters in Cambridge, Massachusetts. Customer testimonials emphasize ease of use, image quality, portability, and utility for patient education and anterior segment documentation. Phelcom has received investment backing from established healthcare and life science funds, signaling credibility in the medical device space.

Ophthalmic Labs, Inc. is a supplier of ophthalmic imaging equipment and software solutions for eye care facilities. The company specializes in fundus cameras (new and refurbished), photo slit lamps, and digital imaging systems used for comprehensive eye examination and documentation. Core product lines include OVision™ imaging software (FDA 510(k) cleared), which enables digital photography and system upgrades; fundus camera sales and service; photo slit lamp systems; and legacy system migrations including IMAGEnet®, Merge/OIS Eye Station, OphthaVision, Canon®, and Visupac® platforms. The company offers both new equipment sales and refurbished units, digital conversion upgrades for obsolete legacy systems, and comprehensive service and refurbishment support. Ophthalmic Labs serves ophthalmology practices and eye clinics requiring diagnostic imaging and documentation capabilities. The company maintains parts inventory, provides maintenance services, and facilitates system migrations to modern Windows 10-based OVision™ platforms. FDA 510(k) clearance is prominently displayed, indicating regulatory compliance for imaging software and devices.

Intelon Optics is a medical device company specializing in advanced Brillouin Optical Scanning System (BOSS®) technology for real-time, high-resolution 3D biomechanical imaging. The FDA-cleared and CE-marked BOSS® for Ophthalmology provides non-contact measurement of ocular-tissue elasticity and stiffness, enabling evaluation of corneal biomechanics, keratoconus assessment, and glaucoma/corneal pathology analysis. The company also offers BOSS® LS for label-free, sub-micron 3D cellular and tissue research, and BOSS® IVF, a research platform analyzing viscoelastic properties of oocytes, embryos, and sperm for reproductive science applications. With extensive clinical validation and adoption by leading eye clinics and universities globally, Intelon Optics addresses unmet diagnostic needs in refractive surgery planning, keratoectasia prediction, and biomechanical tissue characterization across ophthalmology and life sciences research.